2016 Alport Syndrome Award Recipients

Dr. Hirofumi KaiKai

Kumamoto University - Japan

Search for therapeutic reagents by modeling Alport syndrome in mice and humans

2016-2018:  $100,000
Category:  Alport Syndrome

Dr. Kai’s group is currently investigating the molecular mechanisms of chronic diseases such as Alport Syndrome, cystic fibrosis, amyloidosis, diabetes and COPD. His group’s main goal is to elucidate the factors involved in these diseases which could ultimately provide useful information to develop therapy. Specifically, they study 1) drug development based on the intracellular trafficking and degradation of type IV collagen, ion channels, transporters, and transthyretin, 2) the innate immunity molecules in the epithelial cells, 3) cell biology of physical stress and development of physical medicine. Dr. Kai is a leading member of the Japanese Pharmacological Society and collaborates with pharmaceutical companies as a technical advisor and consultant to enhance new drug development.

In partnership with the Alport Syndrome Foundation, the Pedersen Family and The Kidney Foundation of Canada

Dr. Jeffrey MinerMinor

Washington University - St. Louis, Missouri

5-Ht2b antagonism as a strategy to prevent renal function loss in Alport Syndrome

2016-2018:  $100,000
Category:  Alport Syndrome


Dr. Jeffrey Miner is Professor of Medicine and Director of Basic Research in the Division of Nephrology at Washington University School of Medicine in St. Louis, Missouri.  He received his PhD from the California Institute of Technology in 1991 and moved to Washington University for postdoctoral training in 1992. He created a mouse model for Alport syndrome in 1994 and has been studying Alport syndrome and other diseases that impact the kidney’s filtration barrier ever since. He joined the faculty of the Division of Nephrology in 1996 and established a research program that has been funded by the National Institutes of Health, the March of Dimes, the American Heart Association, and the Alport Syndrome Foundation/Pedersen Family/Kidney Foundation of Canada, as well as by pharmaceutical companies.  He is using his mouse model of Alport syndrome to search for new pathways that injure the kidney and to test the effects of drugs that inhibit injurious pathways that lead to loss of kidney function. Dr. Miner received the American Society of Nephrology’s Young Investigator Award in 2004 and chaired ASN’s Biosciences Research Advisory Group from 2012-2016. He is a member of the Editorial Boards of the Journal of the American Society of Nephrology, Kidney International, and the Journal of Clinical Investigation.

In partnership with the Alport Syndrome Foundation, the Pedersen Family and The Kidney Foundation of Canada

National Office - 310-5160 Decarie Blvd., Montreal, QC H3X 2H9 - Tel.: (514) 369-4806 / 1-800-361-7494
Charitable Registration Number: 107567398RR0001